Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.56 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11922686 | 0.84 | SIGMAR1 (0.49) | HRH1LOXL2SIGMAR1KDM4ESMN1; SMN2 | |
| SCHEMBL10926250 | 0.82 | SIGMAR1 (0.47) | HRH1LOXL2SIGMAR1KDM4ESMN1; SMN2 | |
| SCHEMBL8828390 | 0.81 | SIGMAR1 (0.70) | SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9321360 | 0.80 | CYP2A6 (0.65) | HRH1SIGMAR1CYP3A4 | |
| SCHEMBL6430952 | 0.79 | SIGMAR1 (0.49) | LOXL2SIGMAR1KDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL27971485 | 0.79 | HRH1 (0.53) | HRH1LOXL2CHRM2CYP1A2CYP3A4 | |
| SCHEMBL4001727 | 0.77 | KDM4E (0.47) | LOXL2KDM4ESMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL9155641 | 0.76 | SIGMAR1 (0.73) | SIGMAR1CHRM2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1319729 | 0.76 | HRH1 (0.83) | HRH1LOXL2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9162073 | 0.75 | KCNH2 (0.54) | SIGMAR1CHRM2CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236965-B2 | Benzimidazole derivatives and their use as a medicament | IPSEN PHARMA S.A.S. (FR) | 2012-08-07 | — | — | US | disclosed |
| US-8236965-B2 | Benzimidazole derivatives and their use as a medicament | IPSEN PHARMA S.A.S. (FR) | 2012-08-07 | — | — | US | disclosed |
| US-20090170922-A1 | Benzimidazole derivatives and their use as a medicament | SOCIETE DE CONSEILS DE RECHERECHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2009-07-02 | — | — | US | disclosed |
| US-20090170922-A1 | Benzimidazole derivatives and their use as a medicament | SOCIETE DE CONSEILS DE RECHERECHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2009-07-02 | — | — | US | disclosed |
| US-7495110-B2 | Benzimidazole derivatives and their use as GnRH antagonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-02-24 | — | — | US | disclosed |
| US-7495110-B2 | Benzimidazole derivatives and their use as GnRH antagonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-02-24 | — | — | US | disclosed |
| EP-1467974-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS GNRH ANTAGONISTS | SOD CONSEILS RECH APPLIC (FR) | 2007-08-15 | — | — | EP | disclosed |
| US-5607953-A | ANTIISCHEMIC AGENTS | EISAI CO., LTD. (JP) | 1997-03-04 | — | — | US | disclosed |
| EP-0344577-B1 | Butenoic or propenoic acid derivatives | EISAI CO LTD (JP) | 1996-10-09 | — | — | EP | disclosed |
| US-5382595-A | Antiischemic agents | EISAI CO., LTD. (JP) | 1995-01-17 | — | — | US | disclosed |
| US-5177089-A | Antiischemic agent, vasodilator | EISAI CO., LTD. (JP) | 1993-01-05 | — | — | US | disclosed |
| CN-1040366-A | Butenoic acid or acrylic acid derivative | EISAI CO LTD (JP) | 1990-03-14 | — | — | CN | disclosed |
| EP-0344577-A2 | Butenoic or propenoic acid derivatives | Eisai Co., Ltd. (JP) | 1989-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170922-A1 | Benzimidazole derivatives and their use as a medicament | GNRHR, FSHR, KISS1R | HRH1 230/4885LOXL2 4654/4885SIGMAR1 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.